BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36073945)

  • 1. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
    Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
    Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
    J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
    Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
    Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm.
    Singh G; Tolkachjov SN; Farberg AS
    Clin Cosmet Investig Dermatol; 2023; 16():925-935. PubMed ID: 37051586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
    Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
    Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
    Rebeca T; Giselle P; Litchman GH; Rigel DS
    J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
    Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
    J Drugs Dermatol; 2023 Dec; 22(12):7691. PubMed ID: 38051842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
    Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
    J Drugs Dermatol; 2024 Feb; 23(2):54-60. PubMed ID: 38306124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
    Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
    Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
    [No Abstract]   [Full Text] [Related]  

  • 10. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic analysis of cutaneous squamous cell carcinoma reveals a multigene prognostic signature associated with metastasis.
    Wang J; Harwood CA; Bailey E; Bewicke-Copley F; Anene CA; Thomson J; Qamar MJ; Laban R; Nourse C; Schoenherr C; Treanor-Taylor M; Healy E; Lai C; Craig P; Moyes C; Rickaby W; Martin J; Proby C; Inman GJ; Leigh IM
    J Am Acad Dermatol; 2023 Dec; 89(6):1159-1166. PubMed ID: 37586461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
    Au JH; Hooper PB; Fitzgerald AL; Somani AK
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
    Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
    Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Considerations for Integrating Gene Expression Profiling into Cutaneous Squamous Cell Carcinoma Management.
    Arron ST; Blalock TW; Guenther JM; Hyams DM; Ibrahim SF; Koyfman SA; Wysong A
    J Drugs Dermatol; 2021 Jun; 20(6):5s-s11. PubMed ID: 34076385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
    Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
    Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
    J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.
    Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Fargnoli MC; Forsea AM; Frenard C; Harwood CΑ; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
    Eur J Cancer; 2020 Mar; 128():60-82. PubMed ID: 32113941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients.
    Borman S; Wilkinson J; Meldi-Sholl L; Johnson C; Carter K; Covington KR; Fitzgerald AL; Kurley SJ; Farberg AS; Goldberg MS; Monzon FA; Oelschlager K; Cook RW
    Diagn Pathol; 2022 Feb; 17(1):32. PubMed ID: 35216597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased expression of microRNA-20a promotes tumor progression and predicts poor prognosis of cutaneous squamous cell carcinoma.
    Zhang L; Xiang P; Han X; Wu L; Li X; Xiong Z
    Int J Clin Exp Pathol; 2015; 8(9):11446-51. PubMed ID: 26617873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma.
    Cañueto J; Cardeñoso E; García JL; Santos-Briz Á; Castellanos-Martín A; Fernández-López E; Blanco Gómez A; Pérez-Losada J; Román-Curto C
    Br J Dermatol; 2017 May; 176(5):1279-1287. PubMed ID: 27510450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.